Related Experiment Videos

[Laboratory and clinical studies of cefpirome in pediatric field]

T Nishimura1, K Tabuki, S Aoki

  • 1Department of Pediatrics, Osaka Medical College.

Insights

Cefpirome (CPR) demonstrated favorable pharmacokinetics and efficacy in pediatric bacterial infections. This cephalosporin antibiotic showed good tolerability with minimal side effects in clinical studies.

Area of Science:

  • Pharmacology
  • Pediatric Infectious Diseases
  • Antibiotic Therapy

Background:

  • Bacterial infections pose a significant health risk in pediatric populations.
  • Novel antimicrobial agents are crucial for combating resistant pathogens.
  • Cefpirome (CPR) is a fourth-generation cephalosporin with broad-spectrum activity.

Observation:

  • Laboratory and clinical studies were conducted on cefpirome (CPR).
  • CPR was administered via 30-minute drip infusion at a single dose of 20 mg/kg to pediatric patients.
  • Pharmacokinetic parameters including peak serum levels, half-life, and urinary excretion rates were measured.

Findings:

  • Mean peak serum level of CPR was 65.7 ± 2.2 µg/ml, with a mean half-life of 1.49 ± 0.046 hours.
  • Mean urinary excretion rate was 57.0 ± 25.8% within the first 8 hours post-infusion.
  • CPR showed excellent (6 cases) to good (3 cases) clinical outcomes in 9 pediatric patients with bacterial infections, including pneumonia and urinary tract infections.

Implications:

  • Cefpirome exhibits promising pharmacokinetic properties and therapeutic effectiveness in pediatric bacterial infections.
  • The drug was generally well-tolerated, with only minor, transient side effects observed, suggesting a favorable safety profile for pediatric use.

Related Concept Videos